Non-embryo-destructive Extraction of Pluripotent Embryonic Stem Cells: Implications for Regenerative Medicine and Reproductive Medicine

Embryonenerhaltende Gewinnung pluripotenter Stammzellen: Implikationen für die regenerative Medizin und die Reproduktionsmedizin

Authors
R. Dittrich1, M. W. Beckmann1, W. Würfel2

Affiliations
1 Frauenklinik des Universitätsklinikums Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen
2 Kinderwunsch-Centrum München, München

Key words
- stem cell extraction
- embryo-preserving
- preimplantation genetic diagnosis (PGD)
- preimplantation therapy (PIT)

Zusammenfassung

Abstract
On August 1, 2013, the German Patent and Trademark Office issued a patent for the “Non-embryo-destructive extraction of pluripotent embryonic stem cells, stem cells obtained by this process and their uses” (DE 10 2004 062 184 B4). The patent document describes a non-embryo-destructive process to harvest embryonic stem cells from the inner cell mass (ICM) during the blastocyst development stage. The patent application was filed with the German Patent Office in Munich on December 23, 2004 and the patent claim was published in 2006. The patent was granted on August 1, 2013. Processing the patent application was a lengthy affair due to the fact that, for a long time, the prevailing opinion in Germany was that genetic screening of embryos (preimplantation genetic diagnosis) was prohibited under the German Embryo Protection Act (ESchG). A ruling by the German Federal Court in 2010 proved this opinion to be false. Animal studies have provided the evidence that the described procedure is technically feasible; healthy offspring were born after stem cells were harvested from the blastocyst and stored. We report here on a technique for the non-embryo-destructive extraction of pluripotent embryonic stem cells together with potential future applications for stem cells harvested in this manner.

Introduction
Stem cells differ from normally differentiated cells principally through their capacity for unlimited division and their potential to develop into very different cell types with characteristic phenotypes and specialized functions [1]. It is this potential that makes stem cells so interesting for many different applications in pharmacetics and medicine. The main aim is to replace and/or regenerate damaged tissue or tissue which no longer functions adequately [1]. The “classic” method for harvesting stem cells is based on isolating stem cells from preimplantation embryos. However, all established procedures to date result in destruction of the embryo [1]. This makes these techniques extremely controversial from an ethical standpoint. They are

Deutsche Version unter: www.thieme-connect.de/ejournals/gebfra

Bibliography
DOI http://dx.doi.org/10.1055/s-0035-1558183
Geburtsh Frauenheilk 2015; 75: 1239–1242 © Georg Thieme Verlag KG Stuttgart - New York - ISSN 0016-5751

Correspondence
Prof. Dr. rer. nat. Ralf Dittrich
Professor für exp. Reproduktionsmedizin
Frauenklinik
Universitätsklinikum Erlangen
Universität Erlangen-Nürnberg
Universitätsstraße 21–23
91054 Erlangen
ralf.dittrich@uk-erlangen.de
that already now the use of autologous stem cells offers greater benefits than the use of non-autologous donor stem cells. A procedure which allows stem cells to be obtained from the inner cell mass (ICM) without affecting the embryo and its potential to develop could already become important now, in the context of preimplantation genetic diagnosis (PGID). Biopsies of blastocysts are increasingly being used for this type of diagnosis (rather than the original biopsies of cleavage-stage embryos), although it is currently not yet clear which cell entities of the blastocyst offer the most reliable results. Currently there is some evidence that ICM cells would be more useful rather than trophoderm cells.

Below we present and comment on a German federal patent describing a technique which allows individual stem cells to be harvested for their later use in regenerative medicine or reproductive medicine without destruction of the embryo.

**Overview**

**Technique for the non-embryo-destructive extraction of pluripotent embryonic stem cells**

The technique for the non-embryo-destructive extraction of pluripotent embryonic stem cells has been described in detail in the aforementioned patent (DE 10 2004 062 184 B4) [1]. In brief, after fixation of the blastocyst using a holding pipette (Fig. 1a), a channel is opened up through the zona pellucida (the protective external layer of blastocysts) (Fig. 1a). The opening in the zona pellucida is created using any one of a number of different procedures already in use in assisted reproductive medicine. Potential methods include chemical techniques (e.g. the use of acidic Tyrode’s solution), mechanical methods and laser techniques [1]. An instrument to mobilize the stem cells is introduced through the opening and guided through the trophoderm layer until it reaches the inner cell mass (Fig. 1b). The following instruments are used for mobilization: 1, a special pipette with a diameter of approximately 10 µm with a double-sided blade used to detach individual cells from the inner cell mass through careful turning of the pipette. Aspiration of the stem cells which are detached from the inner cell mass is done using either an aspiration pipette or a double-lumen pipette (Fig. 1b).

After harvesting the cells are placed in a suitable culture medium and expanded in accordance with the standard methods used to cultivate embryonic stem cells [1]. The patent lists a number of different cultivation methods to increase the number of stem cells. Cultivation typically consists of culture on mouse fibroblast feeder cell layers. It is also possible to use other feeder cells types, e.g. primary cells, instead of mouse fibroblasts. One method of cultivation consists of plating the cells obtained on a mouse fibroblast layer to create cell accumulations, the removal of these cell accumulations and division of the accumulations into individual groups of cells, followed by repeat plating on fibroblast feeder cell layers. The ES cell medium described in WO 96/22362 consists of 80% DMEM (Dulbecco’s modified Eagle’s medium), 20% fetal bovine serum (FBS), and 0.1 mM β-mercapto-ethanol along with small amounts of other additives, e.g. amino acids, antibiotics, etc., and is commonly used to cultivate embryonic stem cells. However, other well-known cell cultivation media can also be used [1].

**Non-embryod-destructive stem cell extraction**

The standard established methods to harvest human embryonic stem cells (hESC) are based – following the first publication by Dittrich R et al. Non-embryo-destructive Extraction of... Geburtsh Frauenheilk 2015; 75: 1239–1242

![Diagram of a blastocyst showing the channel used to introduce the manipulation pipette](image)

**Fig. 1 a and b**: Diagram of a blastocyst showing the channel used to introduce the manipulation pipette (from [1]). **Fig. 1 b**: Harvesting of mobilized cells from the inner cell mass using a special pipette [1].
Evans and Kaufmann [2] – on the destruction of human embryos [3–7], either during the early cleavage stage or at the blastocyst development stage [3, 8, 9]. “Supernumerary” embryos which may accrue during ART treatment are usually used [5, 10, 11], occasionally also embryos with genetic anomalies (after PGS [pre-implantation genetic screening]) which are not used for embryo transfer (ET) [11, 12]. This approach is legal in many countries – although not in Germany – but remains ethically controversial [13, 14], possibly with the exception of the use of embryos with arrested development [6, 15]. However, in several countries there is no need to harvest embryonic stem cells without destroying the embryo.

Between the years 2006 and 2008, the working group around Robert Lanza published several studies describing the non-embryo-destructive extraction of stem cells in the early cleavage stage [16–19]. It is well known that individual blastomeres obtained with this method have the potential to develop into tissue or organs [20, 21], although even at the 2-cell stage cells exhibit a certain preference to develop further into a trophoblast or into the inner cell mass (ICM) [8]. The ability to develop stem cell lines from biopsies taken in the early cleavage stage has also been reported by other groups [15, 22–24].

The use of ICM cells, i.e. blastocysts, is more difficult [17, 24, 25]. This is basically due to the fact that blastocysts already exhibit cellular polarization [26] into either polarized trophectoderm or non-polarized ICM. This problem can be solved without difficulty through the addition of laminin, with the result that the efficacy of this method for stem cell harvesting approaches that of other techniques [17, 27, 28].

The aforementioned patent describes a method for the non-embryo-destructive extraction of embryonic stem cells from the inner cell mass (ICM) during the blastocyst development stage [1]. The application was filed on December 23, 2004 with the German Patent Office in Munich, and the patent application was published in 2006. The patent was granted on August 1, 2013. The length of time it took to process the patent application was because, for a long time, the prevailing opinion in Germany was that genetic screening of embryos (preimplantation genetic diagnosis [PGD], PGS) was prohibited under the German Embryo Protection Act (EStGB). It took a ruling by the German Federal Court to disprove this opinion [29]. The animal studies we conducted have since provided evidence that the described procedure is technically feasible [30]: healthy offspring were born after stem cells were harvested from the blastocyst and preserved.

Preservation of embryonic stem cells for homologous use

From the perspective of reproductive medicine, the above described procedure allows embryonic stem cells to be preserved during ART treatment. The biopsied stem cells can be immediately cultivated further (expanded) and then cryopreserved. Immediate cryopreservation with storage of the blastomeres in suitable storage containers (e.g. suspended in a matrix for vitrification or in an empty zona pellucida) would also be possible. The goal would be to use these stem cells at a later date for the benefit of the child which developed out of the biopsied blastocyst.

Such early stem cells would undoubtedly have the greatest potential for development, greater than that of fetal or adult stem cells [31, 32]. Moreover, since they would be HLA-identical, there would be no risk of immunopathological reactions as can occur with heterologous stem cells [33, 34]. In the event that after preservation of ICM stem cells the transfer of the blastocyst would not result in a pregnancy and the birth of a child, there would still remain the possibility of allogeneic use.

Biopsy of the inner cell mass (ICM) for PIGD appears to offer more reliable results

Recently a number of studies were published on trophectoderm biopsy (TEB), a technique for PIGD or PGS, which raised several interesting issues [35–37]. The authors of these studies investigated the trophectoderm, the blastocoel fluid, and the inner cell mass from the same blastocyst and found that the respective genetic findings could differ: it is apparently possible that genetic anomalies may be present in trophectoderm cells and in the blastocoel fluid even if the genetics of the ICM are unremarkable. One suggestion, currently being discussed, is that genetically abnormal cells of the ICM are “disposed of” by being transferred to the blastocoel fluid and/or the trophectoderm, and that essentially this constitutes a form of “embryonic self-repair” [38]. If this hypothesis can be confirmed, then the consequence would be that unremarkable genetic findings based on TEB would be reliable, while abnormal findings could not preclude the presence of a genetically unremarkable embryoblast. This would raise several questions – at the very least in this context – about the role of TEB as a technique for PIGD/PGS, with preference having potentially to be given to direct biopsies of the ICM (ICM-B). In this case, the technique described in the patent would offer one means of ICM-B.

The last potential area of application looks more to the future.

Preimplantation therapy (PIT)

One of the main criticisms levelled against PIGD or PGS is the fact that these test methods ultimately result in the rejection of genetically abnormal embryos, which amounts to a negative selection. Particularly in the case of monogenic diseases, the diagnostic techniques have no curative intent; their exclusive goal is to detect genetic abnormalities, not to rectify them. The patented technique offers the potential for some form of “preimplantation therapy” (PIT). However, such PIT concepts are still looking ahead to the future as the genetic correction of monogenic changes is not yet a routine procedure. However, a number of techniques have been described and tested in animal experiments which are working toward that end [39–41]. A means of correcting human trisomy 21 using this method has also already been described in principle [42–44]. If the option to perform such corrections should become an established procedure, then it would be useful to undertake such corrections as early as possible [45]. According to the current state of knowledge, a curative approach would not even require all cells of the ICM to be rectified; the creation of a mosaic, possibly based on reprogramming [46], should suffice to prevent a later clinical manifestation of the associated disease. The same would probably apply to mitochondriopathies.

Conclusion

The method described in the patent allows pluripotent stem cells to be obtained from the inner cell mass of an embryo without destroying the embryo itself or impairing its potential for development. This does not only have technical implications through the description of an additional and new method for stem cell harvesting but also involves other, primarily ethical, considerations, both for current practices in reproductive medicine and for the future. A non-embryo-destructive method for stem cell harvest-
Conflict of Interest

R.D. and M.W.B. declare that they have no conflicts of interest. W.W. declares that he is the holder of patent DE 10 2004 062 184 B4.

References

1 DPMAregister. DE 10 2004 062 184.5. Online: https://register.dpma.de/DPMAregister/?register/TA02010040621845; last access: 20.04.2015
13 Hug K. Sources of human embryos for stem cell research: ethical problems and their possible solutions. Medicina (Kaunas) 2005; 41: 1002–1010
22 Geens M, Mateizel I, Sermon K et al. Human embryonic stem cell lines derived from single blastomeres of two 4-cell stage embryos. Hum Reprod 2005; 24: 2709–2717
24 Cenaria M, Pull E, Cernac et al. Evaluation of bovine embryo biopsy techniques according to their ability to preserve embryo viability. J Biomed Biotech 2012; DOI: 10.1155/2012/541384
35 Tobler KJ, Zhao Y, Ross R et al. Comparative genomic hybridization microarray (aCGH) analysis of DNA isolated from blastocoeles fluid from 26 blastocysts. Fertil Steril 2014; 102 (Suppl.): e183–e184